Study of Mifepristone for Outpatient Induction of Labour in Pregnant Women Randomized Controlled Trial Comparing Mifepristone Plus Standard Care to Placebo

What this Trial Is About

The trial investigates induction of labour in pregnant women, focusing on improving current methods that are often lengthy, costly, and unpleasant. It evaluates the effectiveness and safety of Mifepristone, a drug that could reduce hospital stays and admissions before labour, especially important during the COVID-19 pandemic. The study aims to offer a better outpatient induction option for women at a later stage of pregnancy. Participants will be randomly assigned to receive either Mifepristone 300mg plus standard care or a placebo plus standard care. Treatments are given once, and the study is double-blinded to ensure unbiased results. The main treatment period lasts up to two days after administration, with follow-up extending up to six weeks after delivery to assess clinical outcomes, resource use, patient experience, and safety. Women will be monitored closely during the initial two days after treatment, while still in hospital, to assess labour progress or delivery. Additional follow-ups up to six weeks postpartum will track clinical outcomes, safety, and resource use. The study collects detailed data on labour induction success and experiences, aiming to measure the proportion of women delivering within two days of intervention and effects on hospital resources and patient satisfaction.

Mifepristone Outpatient Labour Induction